⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ENTA News
Enanta Pharmaceuticals, Inc
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025
businesswire.com
ENTA
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
businesswire.com
ENTA
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
businesswire.com
ENTA
Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
businesswire.com
ENTA
Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock
businesswire.com
ENTA
Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
businesswire.com
ENTA